Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine
Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine
复制标题
DOI：
10.1016/j.coviro.2017.03.008
复制
发表时间：
2017-04-01
影响因子：
5.9
通讯作者：
Siegrist, Claire-Anne
中科院分区：
文献类型：
--
作者：
Medaglini, Donata;Siegrist, Claire-Anne
The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.
